Article

Cancer, Hepatitis Drug Approvals Highlight SPT Week in Review

Author(s):

Top news of the week from Specialty Pharmacy Times.

5. Direct-Acting Antivirals Slash the Risk of HCV-Associated Liver Cancer

Patients without cirrhosis who achieved a sustained virological response had the lowest risk of hepatocellular carcinoma linked to hepatitis C virus. Read more.

4. FDA Approves First Treatment for Rare Blood Cancer

Vemurafenib (Zelboraf) receives priority review for Erdheim-Chester Disease. Read more.

3. Alectinib Approved as First-Line Lung Cancer Therapy

Alectinib (Alecensa) found to reduce the risk of disease progression in patients with metastatic non-small cell lung cancer. Read more.

2. FDA Approves Adcentris for Anaplastic Large Cell Lymphoma

Brentuximab vedotin (Adcentris) improves survival among patients with anaplastic large cell lymphoma or CD30-expressing mycosis fungoides. Read more.

1. FDA Approves New Hepatitis Therapy

Heplisav-B is the only 2-dose hepatitis B vaccine recombinant approved in the United States. Read more.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com